The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
The center will deliver Certified Pre-Owned instruments restored to factory-grade standards and backed by Agilent Standard Warranty
The combination also outperformed chemotherapy on another important secondary endpoint
Subscribe To Our Newsletter & Stay Updated